Recurrent idiopathic priapism is a difficult problem to treat and a true emergency for the physicians, and often even invasive therapeutic interventions fail. We recently managed three men with refractory idiopathic priapism with oral gabapentin. They responded to treatment within 48 h. Two men continue not to experience prolonged erections while treated with lower doses of gabapentin for 16 and 24 months, respectively. The third, after a successful treatment for 6 months, stopped gabapentin and priapism recurred. He responded to treatment again and continues to be free of episodes for 9 months. Gabapentin may be a safe alternative for the management of refractory idiopathic priapism.
Introduction
Erection lasting longer than 6 h is an alarming condition and a true medical emergency. Although rare, idiopathic low-flow priapism and especially the recurrent refractory one is a difficult problem to treat even with invasive interventions. 1, 2 Recently, several pharmaceutical factors have been tried to treat this condition in a conservative manner. 3 We herein present our experience with gabapentin in the treatment of refractory idiopathic priapism.
Patients and management
During the last 2 y, we treated three patients with recurrent, refractory, idiopathic low-flow (venoocclusive) priapism with gabapentin. Idiopathic etiology was diagnosed by excluding trauma, hematologic, pharmacologic and neurologic causes. Patient characteristics are shown in Table 1 . All had a history of several priapism episodes, which mainly occurred during night-time sleep, and had undergone several oral treatments or intracavernosal injections of a-adreno-receptor agonists. They also failed to respond to intracavernosal etilephrine.
Patients were given gabapentin 400 mg four times per day. Detumescence was obvious after 24 h. In the third man, the daily dose was increased to 2400 mg and a complete response was recorded after 48 h. Treatment was well tolerated and patients continued gabapentin 300 mg TID. Two men are free of priapism episodes for 24 and 16 months, respectively. The third one after a successful treatment for 6 months stopped gabapentin and priapism recurred. He responded again to 1600 mg of gabapentin, continues treatment with 300 mg TID and remains free of priapism episodes for 9 months. None reported remarkable impairment of erectile function while treated with gabapentin.
Discussion
The cause and the exact pathophysiology of the idiopathic low-flow priapism remain obscure. Secondarily, idiopathic priapism may be caused by several medications and conditions, such as intracavernosal injections for the treatment of erectile dysfunction, hematological and neurological diseases, tumor infiltration and trauma. 3 Ischemic priapism is not the result of enchanced smooth muscle relaxation in most cases (except following intracavernosal injections); rather it can be due to venous trapping, venous outflow obstruction and tumor infiltration. The prolonged full rigidity causes ischemia and smooth muscle hypoxia. In a study of the model of ischemic priapism in experiments, it was clearly proven that the smooth muscle tone, the spontaneous contractile activity and the response to a-agonists depend on the grade of corporal oxygenation. 4 These findings can explain the failure of the injected to penis a-antagonists for the management of priapism.
Gabapentin is a drug with anticonvulsant, antinociceptive and anxiolytic properties, widely used as an analgesic and antiepileptic agent, with an unknown mechanism of action. Recent experience has shown that its doses can be rapidly titrated up to 4800 mg/day, remarkably increasing the efficacy without significant influence on the safety profile. 5 The rationale for the treatment of priapism with this medication was based on the reported sexual dysfunction possibly caused by gabapentin. Three patients treated with gabapentin for epilepsy complained of decreased potency and anorgasmia, which improved when the dosage of gabapentin was tapered or the medication replaced with other antiepileptic drug. 6, 7 In a recent fine study of gabapentin effect in rat hippocampus and neocortex, the results suggested that gabapentin selectively inhibits Ca 2 þ influx by inhibiting voltage-operated Ca 2 þ channels in a subset of excitatory and inhibitory presynaptic terminals, thereby attenuating synaptic transmission. 8 Although the molecular targets of gabapentin remain unknown, the inhibition of Ca 2 þ efflux from muscle cells in the corpora, with a consequent inhibition of smooth muscle relaxation, might explain the effectiveness of gabapentin in the management of refractory priapism. An interesting issue is the ability of these men to have normal erections, although treated with gabapentin. It must be studied whether gabapentin interferes with these erections, as occurs in men with stuttering priapism treated with estrogens or antiandrogens. These treatments, aiming to feedback the inhibition of testosterone or block androgen receptors or downregulate pituitary gland, appear to be effective and most patients are still able to engage in sexual life. 9 Clearly, this preliminary study involves only three cases, and it is actually hard to affirm that the medication is truly effective for this condition. To elucidate gabapentin's clinical efficacy and mechanism of action, a larger series of patients is needed and, possibly, histological in vitro studies should be conducted directly to the cavernous tissue. Gabapentin in idiopathic priapism P Perimenis et al
